|
TNFRSF11B
|
Cardiovascular Diseases
|
0.100 |
Biomarker |
BEFREE |
The OPG/RANKL/RANK system appears to have a role in CVD outcomes.
|
30270544 |
2019 |
|
TNFRSF11B
|
Cardiovascular Diseases
|
0.100 |
Biomarker |
BEFREE |
Osteoprotegerin (OPG) and the receptor activator of nuclear factor κB ligand (RANKL) have been implicated in the pathogenesis of cardiovascular disease.
|
31176082 |
2019 |
|
TNFRSF11B
|
Cardiovascular Diseases
|
0.100 |
Biomarker |
BEFREE |
We measured cardiovascular disease (CVD) [serum osteoprotegerin (OPG), plasma brain natriuretic peptide (BNP), cardio-ankle vascular index (CAVI)], tubular damage [urinary L-type fatty acid binding protein (L-FABP)], and inflammatory [serum tumornecrosis factor (TNF) α and its receptors (TNFRs)] biomarkers in 314 patients with T2D-NA.
|
29729375 |
2018 |
|
TNFRSF11B
|
Cardiovascular Diseases
|
0.100 |
Biomarker |
BEFREE |
Circulating OPG levels could be used as independent biomarkers of cardiovascular disease in patients with acute or chronic cardiometabolic disease and thus an improved prognosis.
|
28867452 |
2018 |
|
TNFRSF11B
|
Cardiovascular Diseases
|
0.100 |
Biomarker |
BEFREE |
Although circulating osteoprotegerin levels are robustly associated with incident cardiovascular disease ( CVD ) in the general population, its relevance as a biomarker among populations at high CVD risk is less clear.
|
30369329 |
2018 |
|
TNFRSF11B
|
Cardiovascular Diseases
|
0.100 |
Biomarker |
BEFREE |
The aim of this review is to discuss the current knowledge and the role of osteoprotegerin in cardiovascular disease.
|
29687784 |
2018 |
|
TNFRSF11B
|
Cardiovascular Diseases
|
0.100 |
Biomarker |
BEFREE |
Therefore, in this study we assessed the implication of osteoprotegerin (OPG) and sclerostin (SCL), two biomarkers associated with cardiovascular disease and bone metabolism, in the clinical spectrum and atherosclerotic disease of patients with axSpA.
|
29303699 |
2018 |
|
TNFRSF11B
|
Cardiovascular Diseases
|
0.100 |
AlteredExpression |
BEFREE |
OPG levels were directly associated with age, the Charlson comorbidity index (CCI), prevalent cardiovascular disease, carotid intima-media thickness, adiponectin, troponin-I and brain natriuretic peptide (BNP).
|
28882110 |
2017 |
|
TNFRSF11B
|
Cardiovascular Diseases
|
0.100 |
Biomarker |
BEFREE |
Osteoprotegerin (OPG) is a potential biomarker for severity and complications of cardiovascular diseases.
|
29018602 |
2017 |
|
TNFRSF11B
|
Cardiovascular Diseases
|
0.100 |
Biomarker |
BEFREE |
Osteoprotegerin has been shown to be increased in cardiovascular disorders and type 2 diabetes mellitus.
|
27743302 |
2017 |
|
TNFRSF11B
|
Cardiovascular Diseases
|
0.100 |
Biomarker |
BEFREE |
Associations appeared stronger at younger age (P = 0.018 for cardiovascular disease), in studies that did not employ statistical adjustment (P = 0.023 for cardiovascular disease and 0.018 for coronary heart disease), and potentially in studies that measured osteoprotegerin in plasma rather than in serum (P = 0.005 for cardiovascular disease and 0.018 for coronary heart disease).
|
28837646 |
2017 |
|
TNFRSF11B
|
Cardiovascular Diseases
|
0.100 |
Biomarker |
BEFREE |
Moreover, serum levels of some metabolic syndrome-related biomarkers, adipokines such as adiponectin and biomarkers of endothelial cell activation and inflammation such as Osteoprotegerin and Asymmetric dimethylarginine have recently been found useful for the prediction of CV disease in these patients.
|
27490206 |
2016 |
|
TNFRSF11B
|
Cardiovascular Diseases
|
0.100 |
GeneticVariation |
BEFREE |
CONCLUSIONS Our meta-analysis provided quantitative evidence that OPG gene polymorphism may be closely related to an increased risk of CVD, especially for rs2073617 T>C and rs2073618 G>C polymorphisms.
|
27068490 |
2016 |
|
TNFRSF11B
|
Cardiovascular Diseases
|
0.100 |
Biomarker |
BEFREE |
Recent studies have revealed that the receptor activator of nuclear factor-kappa B ligand/RANK/osteoprotegerin (RANKL/RANK/OPG) system has an important role in vascular calcification, which is contributory to various cardiovascular diseases and intimately linked to the regulation of blood pressure.
|
25810067 |
2015 |
|
TNFRSF11B
|
Cardiovascular Diseases
|
0.100 |
Biomarker |
BEFREE |
As osteoprotegerin (OPG) is a potential biomarker of cardiovascular disease, this cross-sectional and prospective study aimed at elucidating OPG levels in TS and its relationship to aortic diameter as well as validated cardiovascular risk markers.
|
24923356 |
2015 |
|
TNFRSF11B
|
Cardiovascular Diseases
|
0.100 |
Biomarker |
BEFREE |
Mounting evidence links osteoprotegerin with cardiovascular disease.
|
25301844 |
2014 |
|
TNFRSF11B
|
Cardiovascular Diseases
|
0.100 |
Biomarker |
BEFREE |
Epidemiological data in patients with cardiovascular disease (CVD) indicate that OPG serum levels are associated with several inflammatory markers, myocardial infarction events, and calcium scores, suggesting that OPG may be causative for CVD.
|
25323324 |
2014 |
|
TNFRSF11B
|
Cardiovascular Diseases
|
0.100 |
GeneticVariation |
BEFREE |
No association between OPG gene variants and cardiovascular disease was observed in the whole group of rheumatoid arthritis patients or in anti-CCP positive patients.
|
25184828 |
2014 |
|
TNFRSF11B
|
Cardiovascular Diseases
|
0.100 |
Biomarker |
BEFREE |
Moreover, we aimed to evaluate the significance of MFAP4 as a marker of cardiovascular disease (CVD) and to correlate MFAP4 with other known ECM markers, such as fibulin-1, osteoprotegerin (OPG), and osteopontin (OPN).
|
24349233 |
2013 |
|
TNFRSF11B
|
Cardiovascular Diseases
|
0.100 |
Biomarker |
BEFREE |
The aim of this article is to provide an overview of the main biochemical, physiological, and pathological aspects of OPG biology in cardiovascular disease.
|
23110639 |
2013 |
|
TNFRSF11B
|
Cardiovascular Diseases
|
0.100 |
Biomarker |
BEFREE |
Osteoprotegerin (OPG)/receptor activator of nuclear factor-κB (RANK)/RANK ligand (RANKL) axis, a key regulatory system in bone homeostasis, was recently linked to some cardiovascular disorders for its regulatory functions to myocardial remodeling.
|
22001292 |
2011 |
|
TNFRSF11B
|
Cardiovascular Diseases
|
0.100 |
Biomarker |
BEFREE |
High concentrations of OPG have been associated with the presence of vascular and cardiovascular diseases.
|
21903966 |
2011 |
|
TNFRSF11B
|
Cardiovascular Diseases
|
0.100 |
GeneticVariation |
BEFREE |
Recently, OPG gene polymorphisms have been associated with osteoporosis and early predictors of cardiovascular disease.
|
15292302 |
2004 |
|
TNFRSF11B
|
Cardiovascular Diseases
|
0.100 |
Biomarker |
BEFREE |
OPG may also play a role in cardiovascular disease since mice lacking the OPG gene display arterial calcification.
|
14508625 |
2004 |